Public record

Thyroid: the public record

4 tables from US federal sources. Latest data date: Nov 11, 2026.

Each table is computed from the named federal dataset as of its data date; the method is under each one.

Label

FDA label facts for thyroid

The FDA label read for thyroid (Amerithroid, application ) was last revised on 2026-05-13. It carries no boxed warning. Of the 4 population sections checked, 3 are present: pregnancy, lactation, pediatric use.

FDA label facts for thyroid: the figures
MeasureValueNote
Label revision date2026-05-13
Label readAmerithroid, generic application
Boxed warningNo
Pregnancy sectionPresent
Lactation sectionPresent
Pediatric use sectionPresent
Geriatric use sectionNot present

Source: FDA drug label via openFDA, viewable on NIH DailyMed, data as of Nov 11, 2026

How this was calculated

Selected the most recently revised prescription label for this single ingredient from an original manufacturer, preferring a brand-name application. Checked which sections exist and quoted headings and sentences exactly as printed.

Scope: One label: the newest prescription label for single-ingredient thyroid from an original manufacturer

Read from one label. Labels for other brands, strengths or forms of the same ingredient can differ. A missing section heading does not mean there is no guidance. Read the full label before relying on it.

Download the data (CSV)

Medicaid

Medicaid prescriptions for thyroid by state

State Medicaid programmes paid for 18,437 thyroid prescriptions in 2025, with $796,552 reimbursed before rebates. Ohio reported the most (2,083), followed by Pennsylvania (1,510) and California (1,481); 38 states and territories reported any.

Medicaid prescriptions for thyroid by state: the figures
MeasureValueNote
Prescriptions paid by Medicaid, 202518,437
Total reimbursed before rebates, 2025$796,552
States and territories reporting38with at least one count CMS did not suppress
Ohio2,083 prescriptions$97,246 reimbursed
Pennsylvania1,510 prescriptions$60,023 reimbursed
California1,481 prescriptions$78,596 reimbursed
Oregon1,154 prescriptions$40,574 reimbursed
Illinois1,074 prescriptions$54,023 reimbursed

Source: CMS, Medicaid State Drug Utilization Data 2025, data as of 2025

How this was calculated

Matched each Medicaid product code to the FDA NDC Directory by labeler and product code, kept finished single-ingredient products, then summed prescriptions and reimbursement by state. National roll-up and suppressed rows dropped.

Scope: All single-ingredient thyroid products in the FDA NDC Directory, fee-for-service and managed care, 2025

Counts under 11 are suppressed by CMS and left out, so totals are a floor. Amounts are before rebates. Differences between states reflect programme size and coverage rules. Compounded products are not included.

Download the data (CSV)

Pharmacy cost

Pharmacy acquisition cost (NADAC) for thyroid

Retail pharmacies paid an average of $1.20 per unit for THYROID 120 MG TABLET as of 2026-11-11, compared with $1.19 twelve months earlier (+1.3%). This is a pharmacy purchase cost, not a patient price.

Pharmacy acquisition cost (NADAC) for thyroid: the figures
MeasureValueNote
THYROID 120 MG TABLET$1.20 per unit12 months earlier $1.19 (+1.3%)
THYROID 15 MG TABLET$0.5254 per unit12 months earlier $0.5206 (+0.9%)
THYROID 30 MG TABLET$0.5997 per unit12 months earlier $0.5788 (+3.6%)
THYROID 60 MG TABLET$0.6810 per unit12 months earlier $0.6686 (+1.9%)
THYROID 90 MG TABLET$1.03 per unit12 months earlier $1.03 (+0.1%)
AMERITHROID 120 MG TABLET$1.20 per unitno price on file 12 months earlier

Source: CMS, National Average Drug Acquisition Cost (NADAC), data as of Nov 11, 2026

How this was calculated

Matched NADAC product codes to the FDA NDC Directory, kept finished single-ingredient products, and listed the product descriptions with the most package codes. The earlier price is the same package code in the file one year before.

Scope: Generic versions of thyroid in the weekly NADAC file of 2026-11-11, compared with the file of 2025-11-12

NADAC is the average invoice price retail pharmacies pay, from a voluntary survey. It leaves out rebates, dispensing fees and markups, and it is not what a patient or insurer pays. Compounded products are not surveyed.

Download the data (CSV)

Recalls

FDA drug recalls naming thyroid

FDA enforcement reports list 65 drug recall entries naming thyroid from 2014 to 2026-09-23. 64 of them are for compounded or other unlisted products and 1 for products FDA lists under a label. The most common stated reason was potency out of specification (40 of 65).

FDA drug recalls naming thyroid: the figures
MeasureValueNote
Recall entries on record65
For products FDA lists under an approved or registered label1
For compounded or other unlisted products64matched by the name in the product description
Class I (most serious)22
Class II43
Class III0
Most recent recall reported2026-09-23
Most common stated reasonpotency out of specification40 of 65 entries

Source: FDA, Enforcement Reports (drug recalls) via openFDA, data as of Nov 10, 2026

How this was calculated

Counted enforcement report entries matched by FDA's listed active substance, or by the name in the product description where FDA lists none. Reasons were grouped by keywords in FDA's stated reason.

Scope: Recalls of single-ingredient thyroid products, plus compounded or unlisted products whose description names it

Each recall covers specific lots from one firm and is not a statement about every product with this ingredient. One event can appear as several entries, one per product.

Download the data (CSV)

Articles on Thyroid